Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History

Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo Finance (2025)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(Wt)}else s.style.display="block"},f=function(){d.refreshPanel().then(m).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var h=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(to=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===h&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Jt)),notifLabel:document.querySelector(".".concat(Vt))};io(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

Compare

1.2800 0.0000 (0.00%)

At close: October 10 at 4:00 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for AKBA

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 1.2800
Open 1.2800
Bid 1.2600 x 700
Ask 1.3200 x 100
Day's Range 1.2550 - 1.2900
52 Week Range 0.7800 - 2.4800
Volume 748,781
Avg. Volume 1,797,575
Market Cap (intraday) 269.169M
Beta (5Y Monthly) 0.76
PE Ratio (TTM) --
EPS (TTM) -0.2100
Earnings Date Nov 6, 2024 - Nov 11, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.50

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

www.akebia.com

167

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Industry

More about Akebia Therapeutics, Inc.

Recent News: AKBA

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

AKBAAkebia Therapeutics, Inc.

1.2800

0.00%

Mkt Cap 269.169M